FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

28 letters match. Newest first.

  1. Sanrace Biotechnology Co., Ltd.

    FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.

    High risk
  2. Stokes Healthcare Inc. dba Epicur Pharma

    FDA warned Epicur Pharma over website claims for compounded omeprazole and buprenorphine animal drugs that are false or misleading.

    High risk
  3. Specialty Health Products CO, LLC

    Specialty Health Products was cited for quality-system, unapproved marketing, and listing violations for its Hydro-San and Aqua Cleanse colonic irrigation devices.

    High risk
  4. K.C. Pharmaceuticals, Inc.

    FDA cited K.C. Pharmaceuticals of Pomona, CA, for sterile-drug manufacturing failures, including aseptic practice problems and failed media fills.

    High risk
  5. Longhorn Vaccines and Diagnostics LLC

    Longhorn Vaccines and Diagnostics sold its PrimeStore MTM sample transport device without required quality controls or clearance for claims beyond its approved uses.

    High risk
  6. LiquidCapsule Manufacturing, LLC

    LiquidCapsule Manufacturing failed CGMP (current good manufacturing practice) for OTC drugs, including component identity testing and process validation failures.

    High risk
  7. Foshan Yiying Hygiene Products Co., Ltd.

    Foshan Yiying, a Chinese OTC drug maker, lacked finished-product testing, stability data and process validation; FDA has blocked its imports.

    High risk
  8. Guangxi Yulin Pharmaceutical Group Co. Ltd.

    FDA warned Guangxi Yulin Pharmaceutical Group that its OTC drugs lacked release testing and had data integrity failures.

    High risk
  9. Gussyup LLC dba Private Label Grooming

    FDA found Gussyup LLC, a Henderson, Nevada OTC drug maker, lacking quality oversight and ingredient identity testing; company stopped drug production.

    High risk
  10. Zhejiang Uniquality Nursing Products Technology Co., Ltd. dba ZheJiang YouQuan Care Products Technology Co., Ltd.

    FDA warns Zhejiang Uniquality over inadequate OTC drug component testing and quality oversight; import alert issued.

    High risk
  11. Diamond Chemical Co., Inc.

    Diamond Chemical Co. in East Rutherford, NJ, made OTC hand sanitizers without required ingredient and finished-product testing or process validation.

    High risk
  12. Fuyang Fuchunjiang Canned Food Co., Ltd.

    FDA says Fuyang Fuchunjiang under-processed 230g roasted gluten pouches and lacked retort flow/temperature records.

    High risk
  13. Thuan Thien Producing Trading Limited Company

    FDA warns Thuan Thien that its frozen juices lack validated 5-log pathogen reduction and coconut juice treatment is inadequate.

    High risk
  14. Barsotti Juice Company, Inc.

    FDA warned Barsotti Juice that its organic carrot juice safety plan does not control Clostridium botulinum.

    High risk
  15. Saruhan Kimya Ve Temizlik Urunleri Sanayi Ticaret Anonim Sirketi Corlu Subesi

    FDA found manufacturing violations at Turkish OTC drug maker, including missing identity, release, and stability testing for hand sanitizers.

    High risk
  16. Sol-ti Inc.

    FDA found Sol-ti's ready-to-drink juices lacked validated pathogen controls and required safety monitoring.

    High risk
  17. Juicer Connections, Inc.

    FDA says Juicer Connections shipped juice with juice-safety-plan and sanitation failures and mislabeled watermelon and carrot juices.

    High risk
  18. Zermat International S.A. de C.V.

    FDA warns Zermat International about current good manufacturing practice violations for OTC drugs, including releasing out-of-specification lots without investigation.

    High risk
  19. Oregon’s Wild Harvest, Inc.

    FDA warned Oregon's Wild Harvest after a September 2021 inspection found dietary supplement manufacturing violations: unproven identity and strength tests and foreign material in ingredients.

    High risk
  20. DSP Skin Care LLC

    FDA cites DSP Skin Care for manufacturing failures and unapproved, misbranded Hongosan antifungal drugs.

    High risk
  21. Russ Davis Wholesale Inc

    FDA warns Russ Davis Wholesale of juice safety-plan failures and allergen cross-contact at Eagan, MN ready-to-eat food facility.

    High risk
  22. Yakamoz Sirke Ferm Urunleri Gida Tas San Ve Tic Ltd STI

    FDA says Turkish juice maker Yakamoz lacked a validated HACCP (juice safety) plan for lemon and lime juice.

    High risk
  23. Health Plus Inc.

    FDA warned Health Plus Inc. over manufacturing quality failures in its Super Colon Cleanse laxative made in Chino, California.

    High risk
  24. DSAART, LLC. dba Alpha Aesthetics

    FDA warned Alpha Aesthetics after inspection found unvalidated sterilization and manufacturing, poor complaint handling, and missed injury reports for silicone implants.

    High risk
  25. CellEra LLC

    CellEra LLC's sterile silver wound dressings have repeated quality-system violations and uncleared labeling claims, FDA says.

    High risk
  26. Magnolia Medical Technologies, Inc.

    Magnolia Medical Technologies received an FDA warning letter for current good manufacturing practice violations affecting its Steripath Gen 2 blood collection system.

    Medium
  27. Biotek India

    Biotek India, an OTC drug maker, lacked active-ingredient testing and sold an unapproved 99% isopropyl rubbing alcohol.

    High risk
  28. Dibar Nutricional S. de R.L. de C.V.

    Dibar Nutricional's OTC drugs drew FDA CGMP violations and an import alert over missing testing.

    High risk